Lungs News and Research

RSS

InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

InterMune, Inc. today announced that Health Canada has approved Esbriet (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in adult patients.

3 Oct 2012

New clinical study to determine whether DNA in blood could show early signs of breast cancer

A SIMPLE blood test could one day be a more accurate way to test for the early signs of breast cancer than using mammograms to spot a lump say researchers today, as Breast Cancer Awareness Month gets underway.

3 Oct 2012

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).

1 Oct 2012

EC approves Sosei’s Seebri Breezhaler to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the European Commission has approved Seebri Breezhaler (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg glycopyrronium measured dose per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

1 Oct 2012

Crizotinib effectively treats patients with ALK-positive lung cancer

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Exelixis, Inc. today reported preliminary data from an ongoing phase 1 dose escalation study of cabozantinib in Japan.

1 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

Sorafenib does not improve overall survival among patients with NSCLC

Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. However, a post-hoc biomarker analysis of the trial data that was also presented suggests that patients with EGFR-mutant tumors may benefit.

29 Sep 2012

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD Pharmaceuticals, Inc. today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.

29 Sep 2012

First report to study clonal population of maxillary sinus carcinoma

Knowing how tumors evolve can lead to new treatments that could help prevent cancer from recurring, according to a study published today by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.

29 Sep 2012

New studies reveal real economic and human costs of caring for cancer patients in Europe

New studies that reveal for the first time the real economic and human costs of caring for cancer patients in Europe will be presented during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

MicroDose completes third and final MDT-637 Phase 1 study on RSV infection

MicroDose Therapeutx, Inc., announced today the completion of its third and final Phase 1 clinical study for MDT-637 with its novel inhaled antiviral fusion inhibitor, MDT-637, for the treatment of RSV infection.

29 Sep 2012

Researchers discover way to detect and eliminate troublemaking stem cells

Mayo Clinic researchers have found a way to detect and eliminate potentially troublemaking stem cells to make stem cell therapy safer. Induced Pluripotent Stem cells, also known as iPS cells, are bioengineered from adult tissues to have properties of embryonic stem cells, which have the unlimited capacity to differentiate and grow into any desired types of cells, such as skin, brain, lung and heart cells.

28 Sep 2012

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

For a cancer patient, over-expression of the MYC oncogene is a bad omen. Scientists have long known that in tumor cells, elevated levels of MYC's protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and mortality. Yet decades of research producing thousands of scientific papers on the subject have failed to consistently explain precisely how c-Myc exerts its effects across a broad range of cancer types. Until now, that is.

28 Sep 2012

Conditionally reprogrammed cells help identify effective therapy for HPV-positive RRP

Using a newly discovered cell technology, Georgetown University Medical Center researchers were able to identify an effective therapy for a patient with a rare type of lung tumor. The single case study, reported in the September 27 issue of New England Journal of Medicine, provides a snapshot of the new technology's promising potential; however, researchers strongly caution that it could be years before validation studies are completed and regulatory approval received for its broader use.

28 Sep 2012

New understanding about function of MYC proteins

Scientists may have discovered why a protein called MYC can provoke a variety of cancers. Like many proteins associated with cancer, MYC helps regulate cell growth. A study carried out by researchers at the National Institutes of Health and colleagues found that, unlike many other cell growth regulators, MYC does not turn genes on or off, but instead boosts the expression of genes that are already turned on.

28 Sep 2012

ACS, AGS issue new guidelines for pre-operative care of elderly patients

New comprehensive guidelines for the pre-operative care of the nation's elderly patients have been issued by the American College of Surgeons (ACS) and the American Geriatrics Society (AGS).

28 Sep 2012

Japanese MHLW approves Sosei’s Seebri inhalation capsules to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg administered through the Breezhaler device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease.

28 Sep 2012

Lungs News and Research

InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

New clinical study to determine whether DNA in blood could show early signs of breast cancer

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

EC approves Sosei’s Seebri Breezhaler to treat COPD

Crizotinib effectively treats patients with ALK-positive lung cancer

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Sorafenib does not improve overall survival among patients with NSCLC

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

First report to study clonal population of maxillary sinus carcinoma

New studies reveal real economic and human costs of caring for cancer patients in Europe

Synta announces results from ganetespib Phase 2b trial on NSCLC

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

MicroDose completes third and final MDT-637 Phase 1 study on RSV infection

Researchers discover way to detect and eliminate troublemaking stem cells

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

Conditionally reprogrammed cells help identify effective therapy for HPV-positive RRP

New understanding about function of MYC proteins

ACS, AGS issue new guidelines for pre-operative care of elderly patients

Japanese MHLW approves Sosei’s Seebri inhalation capsules to treat COPD

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News